Mycenax Biotech Inc. (TPEX:4726)
Taiwan · Delayed Price · Currency is TWD 32.40
-0.30 (-0.92%)
At close: Dec 5, 2025
Mycenax Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 649.64 | 683.92 | 652.62 | 732.28 | 774.27 | 665.34 | Upgrade | |
Revenue Growth (YoY) | -3.45% | 4.80% | -10.88% | -5.42% | 16.37% | 70.23% | Upgrade |
Cost of Revenue | 871.33 | 925.28 | 1,028 | 845.95 | 636.66 | 478.81 | Upgrade |
Gross Profit | -221.69 | -241.36 | -375.19 | -113.67 | 137.61 | 186.53 | Upgrade |
Selling, General & Admin | 143.77 | 141.94 | 152.23 | 156.16 | 133.96 | 93.77 | Upgrade |
Research & Development | 78.69 | 78.19 | 75.81 | 144 | 96.13 | 46.5 | Upgrade |
Operating Expenses | 221.64 | 220.18 | 226.91 | 331.32 | 222.94 | 151.13 | Upgrade |
Operating Income | -443.32 | -461.54 | -602.1 | -445 | -85.33 | 35.4 | Upgrade |
Interest Expense | -28.1 | -26.16 | -23.46 | -15.42 | -1.17 | -0.87 | Upgrade |
Interest & Investment Income | 5.08 | 8.53 | 17.66 | 3.8 | 0.31 | 1.48 | Upgrade |
Earnings From Equity Investments | -17.37 | -12.94 | -8.7 | -0.76 | - | - | Upgrade |
Currency Exchange Gain (Loss) | -12.68 | 14.58 | 3.35 | 13.29 | -1.35 | -9.22 | Upgrade |
Other Non Operating Income (Expenses) | -5.81 | -4.96 | 0.75 | 0.21 | -0.11 | 0.9 | Upgrade |
EBT Excluding Unusual Items | -502.2 | -482.5 | -612.5 | -443.87 | -87.65 | 27.7 | Upgrade |
Gain (Loss) on Sale of Assets | 0.22 | - | - | -20.11 | 0.13 | 0.27 | Upgrade |
Other Unusual Items | 1.07 | 1.07 | -71.48 | 1.13 | - | - | Upgrade |
Pretax Income | -489.07 | -469.59 | -683.98 | -462.84 | -87.52 | 27.97 | Upgrade |
Income Tax Expense | -9.6 | -2.46 | -1.13 | -9.21 | 2.34 | -2.98 | Upgrade |
Net Income | -479.46 | -467.13 | -682.85 | -453.63 | -89.86 | 30.95 | Upgrade |
Net Income to Common | -479.46 | -467.13 | -682.85 | -453.63 | -89.86 | 30.95 | Upgrade |
Shares Outstanding (Basic) | 207 | 206 | 206 | 165 | 148 | 128 | Upgrade |
Shares Outstanding (Diluted) | 207 | 206 | 206 | 165 | 148 | 129 | Upgrade |
Shares Change (YoY) | 0.52% | 0.23% | 24.31% | 11.35% | 15.36% | 2.37% | Upgrade |
EPS (Basic) | -2.32 | -2.27 | -3.32 | -2.74 | -0.61 | 0.24 | Upgrade |
EPS (Diluted) | -2.32 | -2.27 | -3.32 | -2.74 | -0.61 | 0.24 | Upgrade |
Free Cash Flow | -293.24 | -522.11 | -426.81 | -777.12 | -1,244 | -86.04 | Upgrade |
Free Cash Flow Per Share | -1.42 | -2.54 | -2.08 | -4.70 | -8.38 | -0.67 | Upgrade |
Gross Margin | -34.12% | -35.29% | -57.49% | -15.52% | 17.77% | 28.04% | Upgrade |
Operating Margin | -68.24% | -67.48% | -92.26% | -60.77% | -11.02% | 5.32% | Upgrade |
Profit Margin | -73.80% | -68.30% | -104.63% | -61.95% | -11.61% | 4.65% | Upgrade |
Free Cash Flow Margin | -45.14% | -76.34% | -65.40% | -106.12% | -160.71% | -12.93% | Upgrade |
EBITDA | -203.95 | -206.91 | -338.27 | -219.7 | 44.33 | 150.83 | Upgrade |
EBITDA Margin | -31.39% | -30.25% | -51.83% | -30.00% | 5.73% | 22.67% | Upgrade |
D&A For EBITDA | 239.37 | 254.63 | 263.83 | 225.3 | 129.66 | 115.43 | Upgrade |
EBIT | -443.32 | -461.54 | -602.1 | -445 | -85.33 | 35.4 | Upgrade |
EBIT Margin | -68.24% | -67.48% | -92.26% | -60.77% | -11.02% | 5.32% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.